Papaverine Hydrochloride

盐酸罂粟碱

Report date: 2023/02/27 17:44:27
NME

Base Information

Drug NamePapaverine Hydrochloride
Drug Alias Name罂粟碱盐酸盐PavabidOxadilene中宝菲林福虹 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action3',5'-cyclic phosphodiesterase inhibitors
Targets3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsSchizophreniaCognition DisordersIschemia +[6] 
Global Approved IndicationsIschemiaVascular DiseasesSpasm
Approved Indications in ChinaIschemiaSpasm
Original Approved Country/TerritoryCanada
Original Approved Date1951/12/31
Country/TerritoryCanadaUnited StatesDenmark +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesSandozOhio State University Comprehensive Cancer CenterNichi-Iko Pharmaceutical Co Ltd +[4] 
Inactive CompaniesUniversity Of Copenhagen
Active IndicationsIschemiaVascular DiseasesSpasm +[4] 
Inactive IndicationsSchizophreniaCognition Disorders

Other Information

ATC CodeA03AD01G04BE02
Related LinksWikipediaDrugBankKEGG